ArticleTranslational oncology2026
A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOvarian cancer (OC) is the second lethal gynecological malignancy, with chemoresistance being a major therapeutic challenge. Interestingly, although malignant ascites is generally associated with poor prognosis, tumor-suppressing factors have been identified in ascitic fluid. This study aims to identify chemotherapy-sensitizing peptides in OC ascites and elucidate its underlying mechanisms.
methodsMass spectrometry was exployed to identify differentially enriched peptides. The feasibility of therapeutic administration was evaluated by an in vivo toxicity assay. The mechanism of peptide was identified through peptide pull-down combined with mass spectrometry, western blots, immunofluorescence, RNA-sequencing, as well as in vitro and in vivo functional analysis.
resultsPeptidome analysis identified 10 upregulated and 8 downregulated peptides in chemoresistant versus chemosensitive OC ascites. Among these, CPAP1 demonstrated platinum-sentitizing effects. Its membrane-penetrating modified version, TAT-CPAP1, showed enhanced stability, improved anti-proliferation effects and improved platinum sensitivity in both TP53 wild-type A2780 and its chemoresistant counterpart cells. Administration of TAT-CPAP1 showed no apparent liver and kidney damage. Mechanistically, TAT-CPAP1 directly binds and colocalizes with NOLC1 in the nucelus, and alters the expression of genes within the DNA damage response pathway. Both TAT-CPAP1 treatment or NOLC1 knockdown improved the platinum sensitivity, increased MDM4/MDM2 ratio and promoted cytoplasmic MDM4 localization.
conclusionsThe TAT-modified, ascites-derived peptide CPAP1 enhances platinum sensitivity in TP53 wild-type OC cells by targeting NOLC1 and modulating MDM2 and MDM4 expression, while exhibiting no detectable hepatotoxicity or nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.